ESR1 and breast neoplasm: As ESR1 mutations are detected in 15–30% of breast tumors, several studies evaluated hotspot ESR1 mutations using ddPCR in the plasma of patients with primary or metastatic breast cancers or with resistance to endocrine therapy.